TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07326592: A Phase 4, Multicenter, Double-blind, Study to Investigate the Efficacy, Safety, and Tolerability of 3 Active Doses of Respreeza® / Zemaira® Weekly Intravenous Infusions Administered Over 3 Years as Longterm Maintenance

Sponsor: CSL Behring · Phase: PHASE4 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 270 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,499,200

Rescue Site Savings

+$5,604,160

Unlock Full NCT07326592 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07326592 Rescue Dossier →